229 related articles for article (PubMed ID: 29504582)
21. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
23. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
24. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
25. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
Semler O; Netzer C; Hoyer-Kuhn H; Becker J; Eysel P; Schoenau E
J Musculoskelet Neuronal Interact; 2012 Sep; 12(3):183-8. PubMed ID: 22947550
[TBL] [Abstract][Full Text] [Related]
26. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
27. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate therapy for osteogenesis imperfecta.
Phillipi CA; Remmington T; Steiner RD
Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
30. Therapy with pamidronate in children with osteogenesis imperfecta.
Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
[TBL] [Abstract][Full Text] [Related]
31. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
32. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
[TBL] [Abstract][Full Text] [Related]
34. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
35. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Yamashita S
Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
[TBL] [Abstract][Full Text] [Related]
36. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
[TBL] [Abstract][Full Text] [Related]
38. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
39. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.
Shi CG; Zhang Y; Yuan W
Am J Ther; 2016; 23(3):e894-904. PubMed ID: 25844482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
